NO20041996D0 - Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI) - Google Patents

Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Info

Publication number
NO20041996D0
NO20041996D0 NO20041996A NO20041996A NO20041996D0 NO 20041996 D0 NO20041996 D0 NO 20041996D0 NO 20041996 A NO20041996 A NO 20041996A NO 20041996 A NO20041996 A NO 20041996A NO 20041996 D0 NO20041996 D0 NO 20041996D0
Authority
NO
Norway
Prior art keywords
tfpi
administration
treatment
tissue factor
pathway inhibitor
Prior art date
Application number
NO20041996A
Other languages
English (en)
Norwegian (no)
Inventor
Abla Abu-Zayyad Creasey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO20041996D0 publication Critical patent/NO20041996D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20041996A 2001-10-15 2004-05-14 Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI) NO20041996D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
PCT/US2002/032624 WO2003032904A2 (en) 2001-10-15 2002-10-15 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
NO20041996D0 true NO20041996D0 (no) 2004-05-14

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041996A NO20041996D0 (no) 2001-10-15 2004-05-14 Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)
NO20041997A NO20041997D0 (no) 2001-10-15 2004-05-14 Behandling av sepsis ved lavdoseadministrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041997A NO20041997D0 (no) 2001-10-15 2004-05-14 Behandling av sepsis ved lavdoseadministrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)

Country Status (17)

Country Link
US (2) US7674769B2 (OSRAM)
EP (2) EP1446140A4 (OSRAM)
JP (5) JP2005506345A (OSRAM)
KR (2) KR20050036867A (OSRAM)
CN (2) CN1604790A (OSRAM)
AU (2) AU2002365131B2 (OSRAM)
BR (2) BR0213293A (OSRAM)
CA (2) CA2463738A1 (OSRAM)
EA (2) EA200400548A1 (OSRAM)
HU (2) HUP0500472A2 (OSRAM)
IL (2) IL161407A0 (OSRAM)
IS (2) IS7224A (OSRAM)
MX (2) MXPA04003547A (OSRAM)
NO (2) NO20041996D0 (OSRAM)
PL (2) PL372138A1 (OSRAM)
WO (2) WO2003055442A2 (OSRAM)
ZA (2) ZA200403601B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372138A1 (en) * 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
ATE516306T1 (de) 2003-08-13 2011-07-15 Novartis Vaccines & Diagnostic Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
CN101180074A (zh) * 2005-04-15 2008-05-14 诺华疫苗和诊断公司 通过施用组织因子通路抑制剂(tfpi)治疗严重社区获得性肺炎
CA2607293A1 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of tfpi to treat severe bacterial infections
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
KR20080071116A (ko) * 2005-06-24 2008-08-01 드럭리큐어 에이피에스 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질ｃ의 기도 투여법
KR20080040676A (ko) * 2005-07-22 2008-05-08 노파르티스 아게 항미생물제로서의 ｔｆｐｉ 단편
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
CN103974710B (zh) 2011-11-15 2016-07-06 旭化成制药株式会社 用于败血症的治疗和/或改善的药物
MX2015014198A (es) 2013-04-12 2015-12-11 Morphosys Ag Anticuerpos cuyo objetivo es m-csf.
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
CN118715235A (zh) * 2022-01-30 2024-09-27 西湖大学 预防和/或治疗由分支2菌株引起的艰难梭菌感染的组合物和方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
JPS61502166A (ja) 1984-04-19 1986-10-02 アグラシタス 植物細胞の形質転換のための改良された方法及びベクタ−
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
PT98779B (pt) 1990-08-27 1999-06-30 Monsanto Co Processo para a preparacao de uma composicao anticoagulante contendo inibidor sulfatados e metodos para a sua utilizacao
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
DE69327314T2 (de) 1992-06-01 2000-04-13 Chiron Corp., Emeryville Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
AU4408493A (en) 1992-06-11 1994-01-04 Washington University Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
ES2248818T3 (es) 1995-06-07 2006-03-16 Chiron Corporation Metodo de solubilizacion, purificacion y replegamiento de proteinas.
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
WO1997035609A1 (en) 1996-03-25 1997-10-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Neovascularization inhibitor containing tissue factor pathway inhibitor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
WO1998033920A2 (en) * 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
KR100450856B1 (ko) 1997-04-28 2004-10-02 일라이 릴리 앤드 캄파니 활성 단백질 ｃ 제제
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
WO2000030677A1 (en) 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
WO2000077254A1 (en) * 1999-06-11 2000-12-21 The Government Of The United States Of America As Represented By The Secretary, Of The Department Of Health And Human Services Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
CZ305123B6 (cs) 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
WO2001049315A1 (en) 2000-01-06 2001-07-12 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1267904A4 (en) 2000-02-16 2006-02-08 Univ Northwestern POLYPEPTOIDE PULMONARY SURFACTANTS
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DE60217835D1 (en) 2001-02-28 2007-03-15 John H Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
US6808927B2 (en) 2001-04-04 2004-10-26 American Diagnostica, Inc. Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
PL372138A1 (en) * 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
EP1446140A4 (en) 2007-03-07
IL161407A0 (en) 2004-09-27
NO20041997D0 (no) 2004-05-14
WO2003032904A2 (en) 2003-04-24
IS7224A (is) 2004-04-15
US20030139339A1 (en) 2003-07-24
KR20050036867A (ko) 2005-04-20
ZA200403601B (en) 2006-06-28
IL161408A0 (en) 2004-09-27
WO2003055442A3 (en) 2004-03-04
US7674769B2 (en) 2010-03-09
AU2002340183B2 (en) 2008-11-13
JP2006008706A (ja) 2006-01-12
CA2463738A1 (en) 2003-07-10
EA200400549A1 (ru) 2005-02-24
PL372138A1 (en) 2005-07-11
BR0213292A (pt) 2006-05-23
AU2002365131A1 (en) 2003-07-15
JP2005515214A (ja) 2005-05-26
EP1446138A2 (en) 2004-08-18
CA2463655A1 (en) 2003-04-24
IS7223A (is) 2004-04-15
EP1446140A2 (en) 2004-08-18
HUP0501111A2 (en) 2007-12-28
EP1446138A4 (en) 2007-03-14
PL374506A1 (en) 2005-10-31
EA200400548A1 (ru) 2005-06-30
AU2002365131B2 (en) 2007-03-01
CN1604787A (zh) 2005-04-06
ZA200403690B (en) 2005-03-08
JP2010006839A (ja) 2010-01-14
CN1604790A (zh) 2005-04-06
KR20040040489A (ko) 2004-05-12
JP2006008704A (ja) 2006-01-12
HUP0500472A2 (hu) 2005-08-29
MXPA04003548A (es) 2004-07-22
WO2003032904A3 (en) 2004-03-04
BR0213293A (pt) 2004-12-21
US20030139340A1 (en) 2003-07-24
MXPA04003547A (es) 2004-07-22
WO2003055442A2 (en) 2003-07-10
JP2005506345A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
NO20041996D0 (no) Behandling av alvorlig pneumoni ved administrering av vevsfaktor-reaksjonsveiinhibitor (TFPI)
BR0012450A (pt) Benzimidazóis substituìdos
ATE296619T1 (de) Feste orale dosierungsform von simethicon
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
PT2527342E (pt) Derivados do éster cíclico uk-2a úteis para a prevenção ou tratamento de doenças fúngicas
NO20034523L (no) Pyrazolderivater for behandling av HIV
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
NO20033373L (no) Forebyggelse av diabetes ved administrering av GnRH- antagonister
EP1461027A4 (en) TREATMENT OF NEOPLASIA
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
WO2003051838A3 (en) Protein kinase inhibitors
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20003799D0 (no) Innkorporering av kolesterol-senkende midler i konfektdosisformer
WO2004060261A3 (de) Verbindungen, die faktor viia-aktivtat inhieren
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
AU2001258598A1 (en) Use of metal compounds to treat gastrointestinal infections
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
IL178115A0 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
ZA200708700B (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (TFPI)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application